

Evaluation Report for Category B, Subcategory 2.4, 2.6, 3.9, 3.11, 3.12 Application

Application Number: 2009-1426
Application: B.2.4 (changes in product chemistry – proportion of formulants)
B.2.6 (changes in product chemistry – new combination of TGAIs)
B.3.9 (changes to product label – level of control)
B.3.11 (changes to product label – new pests)
B.3.12 (changes to product label – new site or host).
Product: K9 Advantix IGR 55
Registration Number: 29780
Active ingredients (a.i.): Imidacloprid [IMI], Permethrin [PFL], Pyriproxyfen [PRX]
PMRA Document Number : 1945078

Purpose of Application

The purpose of this application is to register a new end-use product, K9 Advantix IGR 55, based on a precedent product, K9 advantix 55 Flea and Tick Adulticide (Registration Number 27660). Related submissions 2009-1397, 2009-1398 and 2009-1399 are for the same product, packaged in different sized doses, for larger and smaller hosts.

Chemistry Assessment

K9 Advantix IGR 55 is formulated as a solution containing imidacloprid at a nominal concentration of 8.8 %, Permethrin at 44.0 % and Pyriproxyfen at 0.44%. This end-use product has a density of 1.14 g/cm³ and pH of 3.74. With the exceptions of storage stability and corrosion characteristics, the chemistry requirements for K9 Advantix IGR 55 are complete.

Health Assessments

K9 Advantix IGR 55 is of low acute toxicity by the oral, dermal and inhalation routes, is moderately irritating to the eye and mildly irritating to the skin, and is not a dermal sensitizer. No adverse effects were noted at the exaggerated dose used in a Safety to Treated Animals study conducted using adult dogs. The results of this study indicate that the product is deemed safe to use on adult dogs when applied according to label directions. However, adverse effects were observed in a similar study in puppies at exaggerated doses, and no assurance of the safety of the products at the label rate was demonstrated in the study. Therefore, the study does not provide assurance that the product is safe for use on puppies.

An occupational risk assessment was not performed for K9 Advantix IGR 55 because the use pattern fits within the existing use profiles for pyriproxyfen, imidacloprid and permethrin. The potential exposure to the applicator and the post-applicator is not expected to exceed that of registered products.

A food residue assessment was not required for this application.

Environmental Assessment

An environmental assessment was not required for this application.

Value Assessment

K9 Advantix IGR 55 contains a combination of active ingredients, which are used to kill all stages (i.e., eggs, larvae and adults) of fleas and adult ticks on dogs. It is a similar product to K9 Advantix 55 Flea and Tick Adulticide (Registration Number 27660; 8.8% imidacloprid and 44% permethrin), which is used to kill the adults of fleas and ticks on dogs.

K9 Advantix IGR 55 also contains 0.44% pyriproxyfen, which prevents the eggs and larvae of fleas from developing into adults. Pyriproxyfen is registered at similar concentrations in other products (i.e., Advantage Plus 55; Registration Number 27582; 9.1% imidacloprid and 0.46% pyriproxyfen).

Conclusion

The PMRA has completed an evaluation of the subject application and has found the information sufficient to register the new end-use product, K9 Advantix IGR 55.

References

PMRA Reference Number

- 1747332 2008, Formulation Type, DACO: 3.5.4 CBI
- 1747334 2008, Oxidizing or Reducing Action, DACO: 3.5.8 CBI
- 1747333 2008, Container Material and Description, DACO: 3.5.5
- 1747336 2008, Explodability, DACO: 3.5.12 CBI
- 1747341 2008, K9 Advantix IGR 10, 20, 55, 100, DACO: 10.1, 10.2.3.1, 10.2.3.2, 10.3.1, 10.3.2
- 1747342 2008, Description of Pest Problem, DACO: 10.2.2
- 1747343 2008, Mode of Action, DACO: 10.2.1
- 1747344 2007, Chemistry Evaluation for K9 Advantix plus Pyriproxifen (Containing Imidacloprid, Pyriproxifen and Permethrin), DACO: 3.2.1, 3.2.2, 3.2.3, 3.3.1, 3.4.1, 3.4.2 CBI
- 1747346 2006, Chemistry Evaluation for K9 Advantix plus Pyriproxifen (Containing Imidacloprid, Pyriproxifen and Permethrin), DACO: 3.5.11, 3.5.2, 3.5.6, 3.5.7, 3.5.9 CBI
- 1747354 2006, Acute Oral Toxicity Up and Down Procedure in Rats, DACO: 4.6.1
- 1747355 2006, Acute Dermal Toxicity Study in Rats - Limit Test, DACO: 4.6.2
- 1747356 2006, Acute Inhalation Toxicity Study in Rats - Limit Test, DACO: 4.6.3
- 1747358 2006, Primary Eye Irritation Study in Rabbits, DACO: 4.6.4
- 1747359 2006, Primary Skin Irritation Study in Rabbits, DACO: 4.6.5
- 1747360 2006, Dermal Sensitization Study in Guinea Pigs (Buehler Method), DACO: 4.6.6
- 1747362 2006, Evaluation of the General Safety of Imidacloprid/Permethrin/Pyriproxifen Spot - On Formulation in Adult Beagle Dogs, DACO: 4.9
- 1747363 2006, Evaluation of the General Safety of Imidacloprid/Permethrin/Pyriproxifen Spot - On Formulation in 7-Week-Old Puppies, DACO: 4.9
- 1790298 2009, K9 Advantix IGR-blank scan M854S04, DACO: 3.4.1 CBI
- 1917157 Health Canada (2010). Evaluation of Flea and Tick Control Products. March 16th 2010.

ISSN: 1911-8082

© Her Majesty the Queen in Right of Canada, represented by the Minister of Public Works and Government Services Canada 2010

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of the Minister of Public Works and Government Services Canada, Ottawa, Ontario K1A 0S5.